Antibodies to the ED-B domain of fibronectin, their constructs and uses

Abstract

This patent describes the selection, production and characterisation of two human, recombinant single-chain Fv antibodies against the B-domain of fibronectin, which is found in the foetal form of the extracellular matrix glycoprotein but, more importantly, is expressed in the neovasculature of proliferating tumours. Given the current excitement and media interest in anti-angiogenic cancer therapies, this product is well-timed and is a promising targeting agent for site-specific delivery of effectors to tumour vasculature. Targeting the tumour vasculature as opposed to the tumour itself is an exciting approach in the area of cancer therapeutics and these antibodies add to the growing armamentarium of anti-angiogenic agents under development.

• angiogenesis
• fibronectin
• single-chain Fv
• tumour vasculature